MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
Elevation Pharmaceuticals, Inc.
Attachments
Elevation Pharmaceuticals
Parents
*Architects: Drug Delivery (Inhalation, Nasal, Powder)
*Architects: Pulmonology (COPD-Chronic Obstructive Pulmonary Disorder), Emphysema
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
*Industry: San Diego, California
Venture Capital: Series B
Children
Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy (2012)
Elevation Pharmaceuticals Pulls in 17 Million to Advance Lung Drug Trial; Presents Positive Results (2011)
Elevation’s lead product candidate, EP-101, is believed to be the only nebulized LAMA being developed for COPD.
he Company's initial focus is on developing novel therapies for the underserved subpopulation of COPD patients not able to effectively control their disease with dry powder or metered dose inhalers.
investors include Canaan Partners, TPG Biotech, Care Capital and Mesa Verde Venture Partners.
San Diego, California